secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2025-08-05T23:59:59+00:00
Accession:  0001193125-25-173010
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials
--------------------------------------------------------------------------------

- Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.
- OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.
- Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.
- Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.
- Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/0001193125-25-173010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000119312525173010/d12427d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-173010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer